The targeted analysis of MDM2 in a well-characterized cohort of GC patients showed that MDM2 amplification is rare, more commonly of intestinal phenotype, although not exclusively, and may not be mutually exclusive with TP53 mutations. This evidence concerns the gene TP53 and gastric cancer.